NTRK1 and breast carcinoma: The EphA2 receptor tyrosine kinase is frequently over-expressed in aggressive breast cancer and has been associated with breast tumor growth in animal models [21], [22] and resistance to therapy with tamoxifen [23], and thus reduction in its expression is currently being considered as a potential target for therapy [24].